Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 3918 is a member of the microRNA family of non-coding RNAs and participates in post-transcriptional gene regulation in multicellular organisms. It is transcribed by RNA polymerase II and processed through the canonical miRNA pathway, becoming part of the RNA-induced silencing complex (RISC). In breast cancer, MIR3918 is reported to suppress cell proliferation, colony formation, and metastasis by targeting downstream genes such as FGFR1. Its downregulation may contribute to tumor aggressiveness, and it functions within ceRNA regulatory networks involving long non-coding RNAs (e.g., CCDC183-AS1) and protein-coding genes. No known drugs directly interact with MIR3918, and its therapeutic potential lies as a molecular biomarker and indirect regulatory element rather than a conventional drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 3918 (MIR3918).